Interestingly, NSCLC patients with concurrent high FABP3 and FABP4 protein expression (FABP3+/FABP4+) had poorer prognosis, and showed shorter survival time significantly than patients with either high FABP3 or high FABP4 protein expression (Figure 3). Here, FABP4 is linked to non-small cell lung carcinoma.